Clinical and genomic analysis of baseline and acquired <em>MET</em> fusions with an intact kinase domain in lung cancer patients

Bo Jin; Yutong Ma; Qian Wu; Qiuxiang Ou; Yang Shao; Shun Xu

doi:10.1016/j.gendis.2023.02.046

您当前的位置：

首页 >

文章列表页 >

Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients

Short communication | 更新时间：2024-02-04

- Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients
- Genes & Diseases Vol. 1, Issue 1, Pages: 76-79(2024)
- 作者机构：
  
  1. Department of Medical Oncology, The First Hospital of China Medical University,Liaoning,Shenyang,China,110001
  2. Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,Jiangsu,Nanjing,China,210000
  3. School of Public Health, Nanjing Medical University,Jiangsu,Nanjing,China,211166
  4. Department of Thoracic Surgery, The First Hospital of China Medical University,Liaoning,Shenyang,China,110001
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.046
  CLC：
- Published：2024，
  
  Published Online：1 January 2024，
扫描看全文
Bo Jin, Yutong Ma, Qian Wu, et al. Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients. [J]. Genes & Diseases 1(1):76-79(2024)
DOI：

Bo Jin, Yutong Ma, Qian Wu, et al. Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients. [J]. Genes & Diseases 1(1):76-79(2024) DOI： 10.1016/j.gendis.2023.02.046.

摘要

Abstract

关键词

Keywords

references

1 T. Fujino, Y. Kobayashi, K. Suda, et al.Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro J Thorac Oncol, 14 (10) (2019), pp. 1753-1765

2 M. Zhuo, Z. Liang, Y. Yi, et al.Analysis of MET kinase domain rearrangement in NSCLC Lung Cancer, 145 (2020), pp. 140-143

3 D. Plenker, M. Bertrand, A.J. de Langen, et al.Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients Clin Cancer Res, 24 (6) (2018), pp. 1337-1343

4 K.D. Davies, T.L. Ng, A. Estrada-Bernal, et al.Dramatic response to crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion JCO Precis Oncol, 2017 (1) (2017) PO.17.00117

5 T. Cheng, Z. Gu, D. Song, et al.Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib J Cancer, 12 (3) (2021), pp. 644-651

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools